OKT3 in severe early rejection: predictors for reversal in renal transplant recipients.
Sumrani
N
N
Department of Surgery, SUNY Health Science Center, Brooklyn 11203.
Delaney
V
V
Rajpoot
D
D
Tejani
A
A
Butt
K
K
Hong
J
J
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3; D011379:Prognosis
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D008775:Methylprednisolone